The Effect of the COVID-19 Pandemic on Frailty in Liver Transplant Candidates
Purpose
Frailty is associated with higher rates of morbidity, mortality, and failure to rescue after major surgical procedures. Sarcopenia is degenerative loss of skeletal muscle mass and strength. It is a key component of physical frailty and is associated with poorer post-surgical outcomes due to decreased patient strength and vitality.
Conditions
- Frailty
- Sarcopenia
- COVID-19
Eligibility
- Eligible Ages
- Between 18 Years and 75 Years
- Eligible Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Age 18 years and older Underwent pre-transplant frailty assessment (PFA) at MDMC
Exclusion Criteria
- Not a patient at Liver Institute at Methodist Dallas
Study Design
- Phase
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Retrospective
Recruiting Locations
More Details
- NCT ID
- NCT05935800
- Status
- Active, not recruiting
- Sponsor
- Methodist Health System
Detailed Description
This study seeks to examine whether the (COVID-19) pandemic, an ongoing global health crisis that was declared a national emergency by the US Federal Government on March 13, 2020, has exacerbated both frailty and sarcopenia in a population of liver transplant candidates.